Registration opens

Keynote: Navigating the Ever-Evolving Health Care Landscape: Perspectives in Leadership & Innovation

The challenges the health care industry face are well understood by those who are seeking to innovate in the field. Yet, the solutions and the approaches needed to anticipate trends versus reacting to sentinel events are still very much needed to ensure that ground-breaking scientific discoveries can have real-world impact on patients, communicates, and societies around the globe. Two seasoned industry leaders will share their perspectives on lessons learned in leadership of teams, organizations, and innovative approaches to industry management.

Jeanne Cunicelli, President, UPMC Enterprises and Executive Vice President, UPMC
BIO

Jeffrey Solomon, President, TD Cowen
BIO

Networking reception

Breakfast

Nails vs. Hammers: Innovation Is the Best Tool for Solving Real World Health Care Challenges

It’s a challenging time in health care but opportunities abound. Health system leaders provide their assessment of the health care landscape, from financial pressures and industry consolidation to digital transformation and opportunities to expand access for patients.

Oscar Marroquin, Senior Vice President, UPMC and President, UPMC Physician Services Division
BIO

Diane Holder, Executive Vice President, UPMC and CEO, UPMC Health Plan
BIO

Tim Billiar, Executive Vice President, UPMC, Chief Scientific Officer, Associate Senior Vice Chancellor for Clinical Academics, University of Pittsburgh
BIO

Jeffrey Solomon, President, TD Cowen
BIO

Keynote Panel: Next-Generation Health Care at its Core — UPMC’s Role in Building a Successful Biotech Ecosystem

An academic health system with expansive provider operations, a large health plan, and a venture capital division drives innovation not only in the care it delivers but also in the value it provides and the innovation it sparks. This progressive model for the modern health system also has ripple effects throughout the community, sparking the growth of a life sciences ecosystem of startups and supporting businesses. This panel convenes leaders of Pittsburgh’s economic revitalization to discuss the vital role of “eds and meds.”

Jeanne Cunicelli, Executive Vice President, UPMC and President, UPMC Enterprises
BIO

Sam Reiman, Director, Richard King Mellon Foundation
BIO

Anantha Shekhar, Senior Vice Chancellor for the Health Sciences and Dean of the School of Medicine, University of Pittsburgh
BIO

Theresa Mayer, Vice President of Research, Carnegie Mellon University
BIO

Coffee and Networking Break

Panel: Expanding the Human Health Span

Tremendous increases in the understanding of the biology of aging and advances in new drugs, such as GLP-1 inhibitors, have led to an exploration of improving the human health span as opposed to simply expanding life span. This session, featuring experts and researchers, will examine the cutting edge of medical research and drug development into weight loss, fasting, and wellness efforts, along with the role of value-based care in ensuring access to treatments for all who need them.

Toren Finkel, Director, the Aging Institute at UPMC and the University of Pittsburgh (Moderator)
BIO

Jennifer Berliner, Director of Physician Well-Being, UPMC
BIO

Anne Newman, Clinical Director, Aging Institute of UPMC and University of Pittsburgh
BIO

Matthew Steinhauser, Associate Professor of Medicine and Deputy Director of the Aging Institute, University of Pittsburgh
BIO

David Moore, Executive vice president, Corporate Development, Novo Nordisk
BIO

Panel: Realizing AI’s Potential in Drug Discovery

Artificial intelligence is being heralded for its potential to improve drug discovery. Where is the technology having the biggest impact, what are the challenges that need to be overcome, and what ethical issues need to be considered? Experts will address these questions and more as the industry grapples with new and revolutionary technologies.

Rob Hartman, Senior Director, UPMC Enterprises (Moderator)
BIO

Joseph Lehar, Senior Vice President of Strategy and Business Development, Owkin
BIO

Colin Hill, CEO and Co-Founder, Aitia
BIO

Virginie Buggia Prevot, Senior Director, Drug Discovery, Valo Health
BIO

Gilan El Saadawi, Chief Medical Officer, Realyze Intelligence
BIO

Lunch

Panel: The Frontiers of Oncology

Harnessing the immune system to fight cancer has seen some early success, especially in blood-borne cancers. But what are the next generation of innovations that will expand the application of immuno-oncology to more cancer types with greater success? This panel of experts dives into the cutting-edge technology and platforms showing the greatest promise.

Mani Mohindru, CEO, Novasenta
BIO

Tullia Bruno, Assistant Professor of Immunology, UPMC Hillman Cancer Center
BIO

Mike Diem, Chief Business Officer, Century Therapeutics
BIO

Keir Loiacono, CEO, BlueSphere Bio
BIO

Deborah Palestrant, Partner, 5AM Ventures
BIO

Panel: Neuroscience and Mental Health: New Targets, Psychedelics, Digital Therapeutics, and Beyond

Advances in neuroscience and the need for solutions to address the mental health crisis will be discussed, including novel molecular targets for CNS conditions, including Alzheimer’s disease, the use of next-generation psychedelics, and the future of digital therapeutics.

Hank Safferstein, CEO, Generian (Moderator)
BIO

Dillan Dinardo, CEO, Mindstate Design Labs
BIO

Craig Thompson, CEO, Cerevance
BIO

Sahil Kirpekar, Chief Business Officer, atai Life Sciences
BIO

Susanne Ahmari, Associate Professor of Psychiatry, University of Pittsburgh
BIO

Coffee and Networking Break

Panel: Enabling Access to Novel Therapeutics in a Value-Based Era

How do stakeholders in health care ensure access to novel therapeutics in a time of pushback against drug costs? The panel will look at the potential for value-based arrangements and other strategies that could allow patients to receive the treatments they need.

Jamie Bauersmith, Vice President, UPMC Enterprises
BIO

Tay Salimullah, Vice President, Global Head Value & Access, Novartis Gene Therapies
BIO

Chronis Manolis, Chief Pharmacy Officer, UPMC Health Plan
BIO

Matthias Kleinz, EVP, Translational Sciences, UPMC Enterprises (Moderator)
BIO

Fireside Chat: Speeding the Regulatory Review of New Drugs

As the FDA accelerates approval pathways for groundbreaking technologies, the head of CBER joins virtually for a fireside chat discussion of recent developments with the programs and what they mean for rare diseases, gene therapies and other novel technologies, and the biotech companies pursuing them.

Peter Marks, Director, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration
BIO

Rob Lin, CEO, Avista
BIO

Panel: Charting a Course for the Future

As the Top of Mind for Life Sciences Summit program wraps up, experts will reflect on key messages from the day’s talks and discuss actionable next steps for participants.

Matthias Kleinz, EVP, Translational Sciences, UPMC Enterprises
BIO

Jonathan Peacock, Chairman, Avantor
BIO

Off-Site Networking Event: Washington Nationals vs. Pittsburgh Pirates, PNC Park